ClinicalTrials.gg
Not yet recruitingNCT07178366DPMAS-ACLFUpdated Nov 6, 2026

Double Plasma Separation and Adsorption in Acute-on-Chronic Liver Failure (DPMAS-ACLF Trial)

An interventional study of Standard medical therapy (SMT) and Double Plasma Molecular Adsorption System (DPMAS) in Acute-on-Chronic Liver Failure (ACLF), sponsored by Institute of Liver and Biliary Sciences, India. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-06.

Sponsored by Institute of Liver and Biliary Sciences, India · Not applicable, Interventional, and Treatment

How we know

Updated Nov 6, 2026Start date movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
56
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 39 studies in Acute-On-Chronic Liver Failure by Institute of Liver and Biliary Sciences, India — 17 open to participants now, 17 under way, 2 of them phase 3. Acute-On-Chronic Liver Failure · Institute of Liver and Biliary Sciences, India.

Planned enrollment
22nd of 28
56 · median 95
Started
2026
with 3 others
No phase
23 of 39
8 open now
Primary completion
2027-07
later than 10 of 16 live
Registered
37th of 39
by date

Among the 39 studies in Acute-On-Chronic Liver Failure by Institute of Liver and Biliary Sciences, India, this one is the 22nd largest by planned enrollment of the 28 interventional ones that give a count, is one of 4 that started in 2026, is one of 23 with no phase, reaches primary completion later than 10 of the 16 other live ones, and was the 37th registered.

Acute-On-Chronic Liver Failure

167 studies on the registry are indexed under Acute-On-Chronic Liver Failure; 61 are open to participants now.

Browse Acute-On-Chronic Liver Failure studies →

Open to participants now

17 of the 39 studies in Acute-On-Chronic Liver Failure by Institute of Liver and Biliary Sciences, India are open now, in 1 country. Recruiting first, the newest first:

11 more — sign in →

By country, each count listing its studies:

All 17 open studies →

Where they have run

Who these studies take

Of the 32 Acute-On-Chronic Liver Failure studies recruiting now, 11 (34%) set no upper age limit and 15 (47%) stop at 75 or younger; 3 take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 39 studies in Acute-On-Chronic Liver Failure by Institute of Liver and Biliary Sciences, India, or all of them as a file.
02

Study summary

Acute-on-chronic liver failure (ACLF) is a serious condition in which patients with chronic liver disease suddenly develop severe liver injury, leading to inflammation, organ failure, and very high short-term mortality. Standard medical treatment can help, but many patients still do poorly without liver transplantation.

This study will test whether Double Plasma Molecular Adsorption System (DPMAS), an extracorporeal blood purification therapy, can improve outcomes in ACLF patients. DPMAS works by filtering the blood through special adsorption columns that remove harmful substances such as bile acids, toxins, and inflammatory molecules.

In this randomized controlled trial, adult patients with ACLF will be randomly assigned to receive either:

Standard medical therapy alone, or

Standard medical therapy plus DPMAS.

The main goal is to see whether DPMAS can improve liver function and reduce disease severity within 14 days. Other outcomes include survival without liver transplant at 28 days, improvement in organ functions, reduction in inflammation, and safety of the procedure.

The study will be conducted at the Institute of Liver and Biliary Sciences (ILBS), New Delhi, India, and will enroll about 56 participants over one year.

Read the detailed description

Acute-on-chronic liver failure (ACLF) is characterized by acute deterioration of liver function in patients with chronic liver disease, leading to systemic inflammation, organ failure, and high short-term mortality. Current treatment is largely supportive, and liver transplantation is often the only curative option, but many patients are not eligible or die while awaiting transplant.

Recent evidence suggests that systemic inflammation, bile acid accumulation, and damage-associated molecular patterns (DAMPs) play key roles in the progression of ACLF. Extracorporeal liver support systems such as plasma exchange have shown benefit in selected patients by reducing inflammation and improving short-term survival.

The Double Plasma Molecular Adsorption System (DPMAS) is a novel extracorporeal therapy that combines plasma separation with sequential adsorption columns. These columns are designed to remove bile acids, bilirubin, cytokines, and other toxins from the circulation. Early studies suggest that DPMAS may improve organ function and reduce mortality in ACLF.

This prospective, open-label, randomized controlled trial will compare standard medical therapy (SMT) alone versus SMT plus DPMAS in adult patients with ACLF (AARC grade II or higher). The primary outcome is an improvement in AARC grade by 1 at day 14 (7 days off treatment). Secondary outcomes include transplant-free survival at 28 days, changes in systemic inflammation, renal and hemodynamic function, bilirubin and bile acid levels, development of infections or new organ failures, and safety of the therapy.

A total of 56 participants will be enrolled and randomized equally into the two study groups. Patients in the intervention arm will undergo a minimum of two DPMAS sessions within the first seven days, with additional sessions as clinically indicated. Participants will be followed for up to 90 days for survival and clinical outcomes.

The study is investigator-initiated and conducted at the Institute of Liver and Biliary Sciences (ILBS), New Delhi, India. Ethical approval has been obtained from the ILBS Institutional Ethics Committee.

03

Conditions studied

  • Acute-on-Chronic Liver Failure (ACLF)

Keywords

  • ACLF
  • DPMAS
  • Lactate
  • Sepsis
  • Liver support
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • ACLF patients of any etiology with systemic inflammatory response syndrome and AARC grade II or more.

Exclusion criteria

Exclusion Criteria:

  • Patients eligible for for severe alcohol-associated hepatitis related ACLF (other than hydrocortisone according to Surviving Sepsis Campaign Guidelines 2021 which is 50 mg iv q 6 h for management of shock
  • Hepatocellular carcinoma or any extrahepatic ,
  • Active fungal sepsis
  • Disseminated intravascular coagulation
  • Hemodynamic instability requiring norepinephrine >0.20ug/kg/min
  • Patients with coma of non-hepatic origin
  • Patients with PaO2/FiO2 ratio \<150
  • Pregnancy
  • Comorbidities associated with poor outcomes (severe cardiopulmonary disease defined by a score >3, or oxygen/steroid-dependent , chronic kidney disease) and patients with post-resection liver failure
  • Patients with fibrinogen \<110 and/or less than 50,000
  • Patients with oliguria with urine output less than 400 ml/day
  • Lack of
  • Patient enrolled in other clinical trials
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
56 participants (estimated)

Study arms

  • Active comparator
    Standard Medical Therapy (SMT) Group

    Participants will receive standard medical therapy alone, which may include nutritional support, lactulose, bowel wash, albumin, vasopressors (norepinephrine/terlipressin), antibiotics, antivirals for HBV reactivation, renal replacement therapy, and intensive care support as per institutional guidelines.

    Other: Standard medical therapy (SMT)

  • Experimental
    SMT + Double Plasma Molecular Adsorption System (DPMAS)

    Participants will receive standard medical therapy plus DPMAS therapy. DPMAS involves extracorporeal liver support using two sequential hemoadsorption cartridges (BS330 ion exchange resin and HA330-II neutral macroporous adsorption resin). A minimum of 2 sessions (3-4 hours each) will be given in the first 7 days, with additional sessions if partial response is observed.

    Other: Standard medical therapy (SMT) · Device: Double Plasma Molecular Adsorption System (DPMAS)

Interventions

  • OtherStandard medical therapy (SMT)

    Standard medical therapy includes nutritional support (25-30 kcal/kg/day), lactulose, bowel wash, albumin, vasopressors (norepinephrine/terlipressin), antibiotics, antivirals for HBV reactivation, renal replacement therapy, and intensive care support as per institutional guidelines.

  • DeviceDouble Plasma Molecular Adsorption System (DPMAS)

    DPMAS therapy uses extracorporeal liver support with two sequential hemoadsorption cartridges (BS330 ion exchange resin and HA330-II neutral macroporous adsorption resin). Minimum 2 sessions (3-4 hours each) are performed within the first 7 days, with additional sessions if partial response is observed.

06

What researchers measure

Primary outcomes

  1. Improvement in AARC ACLF grade by one at day 14 (after 7 days off treatment)

    Proportion of participants who show an improvement of at least one grade in the Asian Pacific Association for the Study of the Liver acute-on-chronic liver failure (AARC ACLF) score at day 14, assessed after a treatment-free interval of 7 days from randomisation.

    Time frame: 14 days

Secondary outcomes

  1. Transplant-free survival

    Proportion of participants alive without liver transplantation at 28 days after randomization.

    Time frame: 28 Days

  2. Change in cytokine levels

    Change in serum cytokine concentrations (IL-6, TNF-α, IL-10) measured by multiplex bead-based immunoassay (e.g., Luminex platform) from baseline to Day 14

    Time frame: 14 days

  3. Change in DAMPs

    Change in circulating damage-associated molecular patterns (HMGB1 and mitochondrial DNA) measured by ELISA and quantitative PCR, respectively, from baseline to Day 14

    Time frame: 14 days

  4. Change in serum bilirubin levels

    Change in serum bilirubin concentration from baseline to Day 14.

    Time frame: 14 days

  5. Change in serum bile acid levels

    Change in serum bile acid concentration from baseline to Day 14.

    Time frame: 14 days

  6. Change in serum creatinine levels

    Change in serum creatinine concentration from baseline to Day 14.

    Time frame: 14 days

  7. Change in urine output

    Change in urine output from baseline to Day 14

    Time frame: 14 days

  8. Change in mean arterial pressure

    Change in mean arterial pressure from baseline to Day 14

    Time frame: 14 days

  9. Change in vasopressor requirement

    Change in vasopressor requirement from baseline to Day 14

    Time frame: 14 days

  10. Incidence of new infections

    Number of participants who develop new infections during the follow-up period

    Time frame: 28 days

  11. Development of new organ failures

    Proportion of participants with new organ failures, assessed using the CLIF-OF score.

    Time frame: 28 days

  12. Safety and tolerability of DPMAS

    Incidence of adverse events such as hypotension, bleeding, sepsis, metabolic disturbances, or allergic reactions during therapy and follow-up.

    Time frame: Upto 90 days

07

Study locations

No study locations are listed for this record.

08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2026; primary completion for Jul 2027, 7 months later.

Of 32 interventional studies with no phase under Acute-On-Chronic Liver Failure, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 50. This study's planned 7 months is below that.

Start moved once since we started tracking on Sep 25, 2026: May 2026 → Dec 2026, on Nov 6, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Sep 11, 2025
First posted
Sep 17, 2025
StartEst.
Dec 15, 2026was May 2026
Primary completionEst.
Jul 2027
CompletionEst.
Oct 2027
Last update
Nov 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
May 10, 2026→Dec 15, 2026
Nov 6, 2026
Show all 1 update
  1. Nov 6, 2026
    Start date May 10, 2026→Dec 15, 2026
    + 1 other change: responsible party

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07178366
Responsible party
Sponsor
First posted
Sep 17, 2025
Start date
Dec 15, 2026 (estimated)
Primary completion
Jul 2027 (estimated)
Completion
Oct 2027 (estimated)
Last update
Nov 6, 2026

Study contacts

Dr. Rakhi Maiwall, MBBS, MD, DM
Contact
rakhi_2011@yahoo.co.in
+91 8750343085

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion